Respiratory companies
29 listed respiratory companies, largest first, with lead program and the next catalyst each has disclosed.
| Company | Ticker | Lead program | Indication | Next catalyst |
|---|---|---|---|---|
| Resmed Inc | RMD | CPAP and connected sleep/respiratory devices | Obstructive sleep apnea and related breathing disorders | — |
| United Therapeutics Corporation | UTHR | Tyvaso DPI / Nebulized Tyvaso (treprostinil) | Pulmonary arterial hypertension (PAH) and PH-ILD | date not stated — FDA decision on IPF sNDA (submitted June 2026) |
| Insmed Incorporated | INSM | BRINSUPRI (brensocatib) / ARIKAYCE | non-cystic fibrosis bronchiectasis; MAC lung disease | H2 2026 — Initiate Phase 3 study in progressive pulmonary fibrosis |
| Liquidia Corp | LQDA | L606 (liposomal treprostinil, inhaled via next-generation nebulizer) | pulmonary hypertension associated with interstitial lung disease (PH-ILD); also PAH (open-label) | October 2026 — RE-WARM Phase 2a dose-finding study (~75 patients) expected to begin October 2026, primary completion targeted February 2027. |
| Vicore Pharma Holding AB | VCRE | buloxibutid | idiopathic pulmonary fibrosis (IPF) | H1 2027 — ASPIRE trial remains on track to report 52-week topline results in mid-2027. |
| Precigen, Inc. | PGEN | Papzimeos (zopapogene imadenovec-drba; PRGN-2012) | recurrent respiratory papillomatosis (adults) | date not stated — EMA review of Marketing Authorization Application (validated, under review) |
| Inspire Medical Systems, Inc. | INSP | Inspire V hypoglossal nerve stimulation system | Moderate to severe obstructive sleep apnea | — |
| Trevi Therapeutics, Inc. | TRVI | Haduvio (oral nalbuphine ER) | Chronic cough in idiopathic pulmonary fibrosis (IPF) | Q4 2026 — Phase 2b LAKE sample size re-estimation |
| Generate Biomedicines, Inc. | GENB | GB-0895 | Severe asthma (long-acting anti-TSLP, Q26W dosing) | 2026 — Phase 1b data readout |
| Avalyn Pharma Inc. | AVLN | AP01 (inhaled pirfenidone) | Progressive pulmonary fibrosis (PPF) | 2026 — Phase 1 study initiation |
| Savara Inc | SVRA | MOLBREEVI (molgramostim inhalation solution) | autoimmune pulmonary alveolar proteinosis (autoimmune PAP) | November 22, 2026 — FDA PDUFA target action date for BLA (extended after a major amendment) |
| Apnimed, Inc. | APMD | AD109 (Oxnimbi) | Obstructive Sleep Apnea (OSA) | February 2027 — PDUFA goal date for NDA review |
| IRulya Therapeutics Inc. | IRLA | LAM-001 | Pulmonary hypertension associated with ILD (PH-ILD); bronchiolitis obliterans syndrome | Q1 2027 — Phase 2 BOS trial results |
| Contineum Therapeutics, Inc. | CTNM | PIPE-791 | idiopathic pulmonary fibrosis (PROPEL-IPF Phase 2); also chronic pain | — |
| Inhibikase Therapeutics, Inc. | IKT | IKT-001 (imatinib prodrug), IMPROVE-PAH | Pulmonary arterial hypertension | date not stated — Topline data readout in Part B of IMPROVE-PAH Phase 3 |
| Upstream Bio, Inc. | UPB | verekitug | Severe asthma, chronic rhinosinusitis with nasal polyps (CRSwNP) and COPD (anti-TSLP receptor antibody) | Q1 2027 — Initiate dosing in Phase 3 trials |
| Pulmonx Corp | LUNG | Zephyr Endobronchial Valve with Chartis Pulmonary Assessment System and LungTraX Platform | Severe emphysema (COPD) | — |
| QTREX Quantum Ltd. | QTEX | INSPIRA ART100 system | oxygenation support for ICU patients with acute respiratory failure | — |
| Gossamer Bio, Inc. | GOSS | seralutinib | pulmonary arterial hypertension (PAH); PH-ILD | Q3 2027 — Potential FDA approval decision if NDA accepted |
| MiNK Therapeutics, Inc. | INKT | agenT-797 | severe pneumonia / moderate-to-severe hypoxemic acute respiratory failure (critical pulmonary immune failure) | 2026 — First patient dosing in investigator-sponsored GvHD prevention Phase 1 trial |
| Rein Therapeutics, Inc. | RNTX | LTI-03 (inhaled Cav1-derived peptide) | Idiopathic pulmonary fibrosis (IPF) | H2 2026 — Company may report data from Phase 2 trial of LTI-03 in the second half of 2026. |
| Connect Biopharma Holdings Ltd | CNTB | rademikibart | acute exacerbations of asthma and COPD (Type 2 inflammation) | date not stated — FDA meeting to align on Phase 3 program |
| Edesa Biotech, Inc. | EDSA | EB05 (paridiprubart) | Acute Respiratory Distress Syndrome (ARDS) | date not stated — Start of Phase 2 proof-of-concept enrollment in vitiligo (Health Canada approved; FDA IND CMC information being provided) |
| Not specified | Not specified | IHL-42X | Obstructive sleep apnea | H1 2027 — DReAMzz Study completion |
| Polyrizon Ltd. | PLRZ | NASARIX allergy blocker (Capture and Contain hydrogel nasal spray) | Allergic symptoms from inhaled airborne allergens (nasal barrier) | H2 2026 — FDA pre-submission meeting (IDE study type and De Novo pathway) |
| aTyr Pharma, Inc. | ATYR | efzofitimod | systemic sclerosis-associated interstitial lung disease (Phase 2 EFZO-CONNECT); pulmonary sarcoidosis new Phase 3 planned | Q1 2027 — Topline data |
| Vivos Therapeutics, Inc. | VVOS | Vivos C.A.R.E. oral appliances (DNA, mRNA, mmRNA appliances) | Mild to severe obstructive sleep apnea and snoring in adults (DNA also moderate-severe pediatric OSA, ages 6-17) | 2026 — Submit and publish trial results |
| Beyond Air, Inc. | XAIR | LungFit PH (nitric oxide generator and delivery system) | persistent pulmonary hypertension of the newborn (PPHN) / hypoxic respiratory failure in term and near-term neonates | 2026 — Discussions with FDA to identify a path forward |
| GRI Bio, Inc. | GRI | GRI-0621 | Idiopathic pulmonary fibrosis (IPF) | H1 2027 — Complete IND-enabling studies, file IND, and begin Phase 1a/1b trial in healthy volunteers |
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.